Home/Pipeline/Digital Model for Parkinson's Disease

Digital Model for Parkinson's Disease

Parkinson's Disease

Development/ValidationActive

Key Facts

Indication

Parkinson's Disease

Phase

Development/Validation

Status

Active

Company

Koneksa Health

About Koneksa Health

Koneksa Health is a New York-based digital health innovator founded in 2014, specializing in using digital biomarkers and AI to transform clinical evidence generation. The company offers a multimodal data platform and expert services that help biopharma clients design smarter, faster, and more patient-centric clinical trials. By unlocking novel signals from complex datasets, Koneksa aims to improve trial efficiency, enhance signal detection, and accelerate therapeutic development across neurology, oncology, respiratory, and rare diseases. It operates as a private, revenue-generating platform and services company trusted by industry leaders.

View full company profile

Therapeutic Areas

Neurology Oncology Respiratory Rare Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active